Market News Comments

Abbott Labs (ABT)

Abbott Laboratories announced that, it has received CE Mark for its XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of critical limb ischemia (CLI) or severe claudication (pain) of the lower leg. CLI is the most advanced form of peripheral artery disease (PAD) that can ultimately lead to limb amputation. With this expanded indication, XIENCE PRIME can be marketed to treat CLI or severe claudication of the lower leg in European Union countries and others that recognize CE Mark.

Jan 20 · 4:57:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Post a Comment


Copyright © 2010
All rights reserved.